source
- Highlight Therapeutics reports positive Phase 2b results for BO-112 in high‑risk head and neck basal cell carcinomaHighlight Therapeutics announced that its Phase 2b study of BO-112 met the primary endpoint of visual and pathological response at week 24 in patients with localized high‑risk head and neck basal c…
- AI health startup Ortet launches with $500M backing from former Genentech AI teamOrtet, a new health-technology company, announced its launch on Tuesday. The firm was founded by three former AI scientists and engineers who previously worked at Roche's Genentech division. Orte…Endpoints · 22d agoDealPositive